Abstract Endoplasmic reticulum (ER) stress leads to activation of the unfolded protein response (UPR) signaling cascade and induction of an apoptotic cell death, autophagy, oncogenesis, metastasis, and/or resistance to cancer therapies. Mechanisms underlying regulation of ER transmembrane proteins PERK, IRE1a, and ATF6a/b, and how the balance of these activities determines outcome of the activated UPR, remain largely unclear. Here, we report a novel molecule transmembrane protein 33 (TMEM33) and its actions in UPR signaling. Immunoblotting and northern blot hybridization assays were used to determine the effects of ER stress on TMEM33 expression levels in various cell lines. Transient transfections, immunofluorescence, subcellular fractionation, immunoprecipitation, and immunoblotting were used to study the subcellular localization of TMEM33, the binding partners of TMEM33, and the expression of downstream effectors of PERK and IRE1a. Our data demonstrate that TMEM33 is a unique ER stress-inducible and ER transmembrane molecule, and a new binding partner of PERK. Exogenous expression of TMEM33 led to increased expression of p-eIF2a and p-IRE1a and their known downstream effectors, ATF4-CHOP and XBP1-S, respectively, in breast cancer cells. TMEM33 overexpression also correlated with increased expression of apoptotic signals including cleaved caspase-7 and cleaved PARP, and an autophagosome protein LC3II, and reduced expression of the autophagy marker p62. TMEM33 is a novel regulator of the PERK-eIE2a-ATF4 and IRE1-XBP1 axes of the UPR signaling. Therefore, TMEM33 may function as a determinant of the ER stressresponsive events in cancer cells.
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Introduction
The endoplasmic reticulum (ER) is involved in several fundamental cellular processes including synthesis and sorting of secretory and membrane proteins, detoxification, and intracellular calcium homeostasis [1] . Correct folding of proteins in the ER lumen is regulated by folding and oxidizing enzymes in the presence of chaperones and glycosylating enzymes dependent on ATP and high Ca2? levels. Misfolded proteins are exported to the cytoplasm for proteosomal degradation by a process known as the ER-associated degradation (ERAD) [2] . ER stress, as defined by the accumulation of misfolded or unfolded proteins above the threshold levels in the ER lumen, leads to activation of an ER-to-nucleus unfolded protein response (UPR) signaling cascade. The ER transmembrane proteins protein kinase RNA-like ER kinase (PERK), inositol-requiring enzyme 1a (IRE1a) and activating transcription factor 6 (ATF6a/b) sense ER stress, each then regulating one of the three distinct axes of the UPR signaling cascade [3] . ER stress-activated PERK phosphorylates serine 51 of eukaryotic translation initiation factor 2a (eIF2a), followed by the suppression of protein synthesis and a selective increase in ATF4 activity. Downstream effectors of PERK signaling include both prosurvival factors such as the transcription factor NRF2 and microRNA miR-211, which are associated with adaptation response, and pro-apoptotic factors including CHOP that can induce cell death [4, 5] . Stress-induced phosphorylation and activation of IRE1a results in activation of the transcription factor X-box binding protein 1 (XBP1) and increased expression of ER chaperones such as GRP78/BiP which, in turn, increase protein folding capacity in the ER lumen. Activated IRE1a also reduces protein load in the ER lumen by cleaving mRNAs encoding secretory and membrane proteins through regulated IRE1a-dependent decay (RIDD).
In the ATF6a/b arm of the UPR signaling, ATF6a/b is transported to the golgi where it undergoes cleavage; cleaved ATF6 (ATF6f/ATF6c) functions as a transcription factor for several ER chaperones. Mechanisms underlying regulation of PERK, IRE1a, and ATF6a/b, and how the balance of these activities determine outcome of the activated UPR, remain largely unclear. Indeed, depending on the acute or chronic ER stress and cellular context, activation of the UPR may lead to apoptotic cell death, senescence, autophagy, oncogenesis, metastasis, and/or resistance to chemotherapeutics and endocrines [6] [7] [8] [9] [10] [11] [12] [13] [14] . Identification of new molecules regulating UPR signals may advance understanding of the mechanistic and functional significance of UPR in cancer biology and therapy.
Here, we report characterization of transmembrane protein 33, TMEM33 (also known as SHINC-3) as a novel ER stress-inducible and ER transmembrane molecule and regulator of two main drivers of the UPR: PERK and IRE1a. Our data show that TMEM33 is a new binding partner of PERK. TMEM33 overexpression led to increased expression levels of both p-eIF2a and p-IRE1a and of their respective downstream effectors, ATF4 and XBP1-S in breast cancer cells. TMEM33 overexpression also led to increased expression of CHOP, cleaved caspase-7, and the autophagosome marker LC3II in these cells. Collectively, this work provides new mechanistic insights into the regulation of PERK and IRE1a signaling pathways via TMEM33 in cancer cells.
Materials and methods
Antibodies, reagents, and chemicals
Rabbit polyclonal antibody was custom generated against a TMEM33-specific peptide, KKVLDARGSNSLPLLR (amino acids 127-143; Covance Research Products Inc., Denver, PA). Polyclonal anti-GAPDH antibody (2275-PC-1) was purchased from Trevigen (Gaithersburg, MD, USA). [15] [16] [17] . LCC1, LCC9, and MCF7RR cells were maintained in IMEM without phenol red and supplemented with 5 % charcoal-stripped calf serum (CCS). All cell cultures were maintained at 37°C under 95 % relative humidity and 95 % O 2 :5 % CO 2 atmosphere.
Construction of Myc-TMEM33 expression vector
TMEM33 cDNA (741 bp) was amplified by RT-PCR using total mRNA from human testes (Ambion, Foster City, CA) and cloned into the pCR2.1 vector (Invitrogen). N-terminal Myc-tagged TMEM33 ORF (771 bp) was amplified by PCR using TMEM33 in pCR2.1 as template. The forward primer sequence containing the translation initiation codon, the Myc epitope (underlined), and Bgl II primer (bold) was 5 0 -GAGATCTGCCATGGAGCAGAAACTCATCTCTG AAGAGGACCTGATGGCAGATACGACCCCGAAC-3 0 , and the reverse primer sequence containing the MulI primer (bold) was 5 0 -GACGCGTCTATGGAACTGTTG GTGCC -3 0 as described earlier [18] . The PCR conditions were as follows: 95°C for 4 min; 40 cycles of denaturation at 94°C for 30 s; annealing at 65°C for 1 min; extension at 72°C for 1 min; and a final extension at 72°C for 5 min. The amplified product was subjected to electrophoresis in 1 % agarose gels and cloned into the pCR3.1 expression vector. TMEM33 cDNA sequence was verified by automated DNA sequencing of both strands using vector-based forward and reverse primers as detailed earlier [18, 19] .
Transient cDNA transfections
COS-1, HEK-293T, and PC-3 prostate cancer cells were transiently transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). HeLa cells were transiently transfected using FuGene HD (Roche), and MCF-7 and MDA-MB231 breast cancer cells were transiently transfected using Lipofectamine LTX (Invitrogen) as described in Supplementary Materials and methods.
Immunofluorescence and immunostaining
COS-1 cells were grown overnight on coverslips placed in a six well plate, one coverslip/well. Approximately, 3 9 10 4 cells were seeded/well. Next day, cells were transfected with 1 lg of Myc-TMEM33 or empty vector using Lipofectamine 2000. Forty eight hours post-transfection, the medium was removed and cells were immediately fixed in 3.7 % paraformaldehyde, followed by immunofluorescence and immunostaining using various antibodies as described in Supplementary Materials and methods.
Subcellular fractionation
Approximately, 5 9 10 6 MCF-7 cells were seeded per 150 mm tissue culture dish. Next day, the cells were collected by trypsinization and washed once with ice-cold phosphate-buffered saline (PBS). The cytosolic, mitochondrial (heavy membrane), microsomal (light membrane), and nuclear fractions were isolated as described in Supplementary Materials and methods.
Immunoprecipitation and immunoblotting
The whole cell lysate (approximately 2 mg protein) was incubated with 25 lL of agarose-conjugated anti-Myc antibody on a rotator at 4°C overnight. The antibodyconjugated agarose beads were washed 1x in cell lysis buffer and used for immunoblotting as reported earlier [20] and detailed in Supplementary Materials and methods.
Thapsigargin and tunicamycin treatments
Stock solutions of thapsigargin (TG, 2 mM) and tunicamycin (TU, 2 mg/mL) were made in DMSO and stored at -20°C. Cells from approximately 80 % confluent monolayers were used. The culture medium was removed and fresh DMEM containing 10 % FBS and the desired final concentration of TG or TU was added to the cells and incubation continued for various periods, followed by cell lysis and Western blotting as described in Supplementary Materials and methods.
Results
TMEM33 is a novel endoplasmic reticulum transmembrane protein
We identified TMEM33 as a novel cDNA fragment (191 bp) in a differentially displayed mRNA screen of cancer cells treated with antisense raf oligonucleotide or control mismatch oligonucleotide [GenBank accession number AF403224]. Subsequent sequential homology search of the human expressed sequence tag (EST) database [21] led to identification of the full-length TMEM33 cDNA sequence (7717 bp) as shown in Fig. 1a . The longest open reading frame of the full-length TMEM33 cDNA encodes a new 247 amino acids (aa) protein (approximately 28 kDa M r ) (Fig. 1b, Supplementary Fig. 1 ). The TMEM33 amino acid sequence revealed three transmembrane helices (32-52 aa, 101-121 aa, and 156-176 aa), at least one phosphorylation site (T65) and two ubiquitination sites (K148 and K221) [22] [23] [24] (Fig. 1b) . Using northern hybridization, four major TMEM33 transcripts (7.7, 4.0, 2.5, and 1.5 kb) were detected in most normal human tissues and cancer cell lines tested (Fig. 2) .
Based on prediction of its likely subcellular localization, the TMEM33 protein appeared to be localized to ER [25] . Subcellular localization of TMEM33 was demonstrated using a combination of immunofluorescence and biochemical fractionation analyses. COS-1 cells were transiently transfected with either a Myc epitope-tagged TMEM33 expression vector (Myc-TMEM33) or empty vector. Immunofluorescence staining showed co-localization of Myc-TMEM33 with Calnexin and ER-tracker but not mito-tracker or WGA staining (Fig. 3a) . Expression of Myc-TMEM33 in COS-1 transfectants was verified by immunoblotting (Fig. 3b) .
Subcellular localization of the endogenous TMEM33 protein was examined by cell fractionation and immunoblotting using a custom-generated rabbit polyclonal antibody against a TMEM33-specific epitope (aa 127-143). The anti-TMEM33 antibody recognized an approximately 28 kDa protein in human prostate cancer cells (PC-3 and DU-145); pre-immune serum had no immune reactivity at the corresponding location (Supplementary Fig. 2a) . The anti-TMEM33 antibody was further validated by sequential immunoblotting of cell lysates from COS-1 Myc-TMEM33 transfectants with anti-Myc and anti-TMEM33 antibodies. These two antibodies recognized an overlapping band at *28 kDa in COS-1 transfectants (Supplementary Fig. 2b ). Using the custom-generated anti-TMEM33 antibody, human endogenous TMEM33 (*28 kDa) was detected in several human cancer cell lines including A549, Aspc-1, Colo-357, MDA-MB435, MCF-7, and HeLa cells (data not shown). In the combined cell fractionation and immunoblotting assay, Calnexin was detected in both the heavy membrane pellet (HM) and the ER-containing microsomal fractions (MS) of MCF-7 cells; heavy membrane pellets contain mitochondrial, lysosomal, and ER-resident proteins. Similar to Calnexin, endogenous TMEM33 expression was seen in both the HM and MS fractions of MCF-7 cells but not in the nuclear or cytosolic fractions (Fig. 3c) . Together with the predicted 2D topology of TMEM33 [26, 27] (Fig. 3d ) these data establish TMEM33 as a novel ER transmembrane resident protein.
TMEM33 is an ER stress-inducible molecule
The ER localization of TMEM33 prompted us to ask whether TMEM33 expression is stimulated in response to known inducers of ER stress including thapsigargin (TG), an inhibitor of ER Ca 2? ATPase, tunicamycin (TU), an inhibitor of N-linked glycosylation, and low glucose. Expression of TMEM33 was analyzed in HeLa cells exposed to TG, TU or low glucose. TMEM33 protein expression was increased in response to ER stress (Fig. 4a, b) . Consistent with these observations, a significant induction of the largest TMEM33 transcript (7.7 kb) was seen in HeLa cells treated with thapsigargin (Fig. 4c) . As expected, GRP78/BiP, a wellknown ER stress-inducible protein chaperone in the ER lumen, was also induced in HeLa cells under similar conditions (data not shown). In addition, ER stress-inducible expression of TMEM33 and GRP78/BiP was also noted in PC-3 prostate cancer cells (data not shown). Thus, TMEM33 is a new ER stress-inducible protein.
TMEM33 overexpression is associated with enhanced stimulation of the ER stressresponsive PERK/p-eIF2a/ATF4 signaling pathway To determine whether TMEM33 is a component of the ER stress-inducible UPR signaling pathway, we first looked for interaction(s) between TMEM33 and the ER membraneresident molecules PERK, IRE1a, and ATF6. HEK293T cells were transiently transfected with the Myc-TMEM33 plasmid and treated with 1 lM TG for various times. Using a reciprocal co-immunoprecipitation assay, our findings show an ER stress-related interaction between TMEM33 and PERK (Fig. 5a ). Myc-TMEM33 did not interact with either IRE1a or ATF6 under similar conditions (data not shown). Next, we examined the effects of TMEM33 overexpression on downstream effectors of activated PERK (p-eIF2a; ATF4). As shown in Fig. 5b and c, and Supplementary Fig. 3 , overexpression of TMEM33 was associated with enhanced basal and ER stress-induced expression of p-eIF2a and ATF4 in Myc-TMEM33 transfectants, relative to empty vector control transfected HEK293T cells. These data establish TMEM33 as a novel binding partner of PERK and demonstrate that TMEM33 overexpression correlates with enhanced activation of the ER stress-inducible PERK/p-eIF2a/ATF4 signaling.
TMEM33 overexpression and increased expression of ER stress-induced cell death signals
We next determined the effects of TMEM33 overexpression on various cell death signals. HeLa cells were transiently transfected with a Myc-TMEM33 or control vector and exposed to TG (1 lM) for indicated times, followed by immunoblotting of whole cell lysates with various antibodies (Fig. 6 ). Fig. 4a ). In addition, Caspase 2 expression was found to be increased in Myc-TMEM33 transfectant COS-1 cells versus control transfectants ( Supplementary Fig. 4a ). Interestingly, expression of cleaved caspase 3 did not seem to change in these cells (data not shown). Furthermore, constitutive expression of cleaved caspase 7 was also seen in TMEM33-transfected Fig. 2 Expression analyses of TMEM33 transcripts in normal human tissues and human cancer cell lines. The mRNA blots (Clontech) were sequentially probed with a radiolabeled TMEM33 cDNA probe, followed by b-actin or GAPDH cDNA probe. S.M., smooth muscle; PBL, peripheral blood lymphocytes; HL-60, promyelogenous leukemia; K-562, chronic myelogenous leukemia; MOLT-4, lymphoblastic leukemia; BL-Raji, Burkitt's lymphoma; SW480, colorectal adenocarcinoma; A549, lung carcinoma; G361, melanoma; DU-145, prostate cancer (Fig. 7, Supplementary Fig. 4b ).
TMEM33 overexpression and constitutive activation of the PERK-p-elF1a-ATF4 and IRE1a-XBP1 axes of the UPR signaling and autophagy in breast cancer cells
To address the consequences of TMEM33 overexpression in human cancer cells, MCF-7 breast cancer cells were transiently transfected with either the Myc-TMEM33 or pCR3.1 vector, followed by immunoblotting of the cell lysates with antibodies against various components of the UPR signaling pathways. Figure 7 shows that exogenous expression of TMEM33 was sufficient to increase basal levels of p-eIF2a, ATF4, CHOP, cleaved caspase 7, p-IRE1a, and XBP1-S but not cleaved ATF6. In addition, cyclin D1 expression, a marker of cell cycle progression and oncogenesis, was decreased in Myc-TMEM33 transfectant MCF-7 cells. The latter observations seem to be inconsistent with data showing high TMEM33 expression in several tumor tissues including breast cancer (Supplementary Fig. 5 ). Moreover, TMEM33 is reported to be amplified in approximately 10 % of breast cancer patient xenografts [28] [29] [30] . During autophagy, microtubule-associated protein-1 light chain 3 (LC3I) is converted to its membrane-bound form (LC3II). We have previously reported that overexpression of XBP1 can regulate autophagy through its control of BCL2 [31] [32] [33] . Increased expression of LC3II and decreased expression of p62/sequestosome 1 (SQSTM1), ubiquitin-binding protein and promoter of apoptosis, was detected in Myc-TMEM33 transfected MCF-7 cells relative to controls (Fig. 7) . Similar observations were made in hormone refractory MDA- MB-231 breast cancer cells (Supplementary Fig. 6 ). Hence, TMEM33 overexpression is associated with constitutive activation of PERK-p-elF1a-ATF4 and IRE1a-XBP1-S signaling and autophagy in breast cancer cells.
Discussion
This expression of TMEM33 with increased autophagy in breast cancer cells. Autophagy has been associated with tumor cell resistance to various therapies. In pilot studies, we also tested whether TMEM33 may serve as a new prognostic marker in certain estrogen receptor-positive breast cancers. Gene expression microarrays were used to measure TMEM33 expression in endocrine-resistant (LCC9, MCF7RR) and sensitive breast cancer cells (LCC1 and MCF7) [15] [16] [17] , and in clinical specimens [34] [35] [36] [37] . TMEM33 mRNA expression was found to be higher in endocrine-resistant breast cancer cells as compared with their matched sensitive control cells. In addition, early recurrent breast cancer specimens showed high TMEM33 expression when compared with non-recurrent breast tumors ( Supplementary Fig. 7 ). Taken together, our current observations suggest a working model where TMEM33 may function as a critical determinant of the balance between PERK and IRE1a-mediated apoptotic, adaptive and neoplastic transformation events in cancer cells (Fig. 8) . How TMEM33 expression is regulated remains unknown. The proximal promoter region of the TMEM33 gene shows putative binding site for NRF-2, a prosurvival transcription factor downstream of the activated PERK ( Supplementary Fig. 1c) . It is tempting to speculate that an as yet unknown combination of feedback and cross-talk exists. For example, where ER stress activates PERK and increases TMEM33 expression via NRF-2, and increased TMEM33 overexpression, depending on the cell type, promotes PERK and IRE-1a activated signaling. TMEM33 may also interact with other proteins. At least one phosphorylation site (Thr 65) and two ubiquitination sites (Lys 148 and Lys 221) are predicted within the open reading frame of TMEM33 (Supplementary Fig. 1b) . TMEM33 may be a member of the family of ubiquitin-modified proteins [38] [39] [40] . The STRING database [41] also predicts potential interaction of TMEM33 with ubiquitin C (UBC), and ubiquitin specific peptidase 19 (USP19), associated with ubiquitin-dependent proteolysis ( Supplementary  Fig. 8 ). TMEM33 may also interact with the retention in endoplasmic reticulum 1 protein (RER1), which is involved in the retrieval of ER membrane proteins from the early golgi compartment (Supplementary Fig. 8 ).
Present report supports the hypothesis that TMEM33 may function as a multi-faceted molecule in cancer cells. While our data suggest that TMEM33 overexpression correlates with enhanced expression of apoptotic signals (CHOP and cleaved caspase7), constitutive expression of TMEM33 was found to be high in a limited number of endocrine-resistant breast cancer cells and in early recurrent breast cancer specimens tested. The latter observations are consistent with the roles of PERK and ATF4 in tumor cell survival [42] . Moreover, autophagy may increase survival of tumor cells [8, 9] . We observed increased expression of autophagosome marker LC3II and downregulation of p62/sequestosome 1 (SQSTM1) in breast cancer cells overexpressing TMEM33, suggesting induction and completion of autophagy. In conclusion, TMEM33 offers a new regulatory mechanism of the UPR and may serve as a determinant of the outcome of activated UPR signaling cascade.
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